Human Domain Antibody Library (DAb library)
Source BioScience LifeSciences™ is pleased to announce the
availability of the Domain Antibody Phagemid library constructed by
Dr Daniel Christ (formally of the MRC Laboratory of Molecular
Biology, Cambridge UK and currently based at the Garvan Institute,
This library offers significant advantages over the
hugely successful Tomlinson I + J library introduced by us in
This artificial library of antibodies can be used to derive
binders to almost any target molecule using phage display and
selection. These binders can be used for the same applications as
conventional monoclonal antibodies (ELISA, Western blotting, FACS,
immunohistochemistry), but can be isolated in a fraction of the
time and without the need for animal immunisation.
Phage-antibody libraries have been used successfully in hundreds
of molecular biology labs worldwide to derive highly specific
antibody reagents to a wide range of different proteins, peptides
or small molecule compounds
This library is based on a VH framework (V3-23/D47). Diversity
was introduced into the antigen binding domains by PCR mutagenesis
into CDR1, CDR2 and CDR3. There are many benefits to this
- Produced binders to the model antigens refold without major
loss of antigen-binding activity upon cooling.
- Antibodies selected maintain antigen-binding activity after up
to 25 cycles of heat denaturation, rivalling the heat resistance of
thermophilic protein such as Taq polymerase.
- Repertoire withstands heat-induced aggregation on phage.
These benefits offer a wide range of diagnostic and therapeutic
research applications and can further maximise the number of
binders to your antigen of interest.
This library is supplied as a single kit containing:
- Phagemid antibody library (~3x10 9 )
- Helper phage KM13
- Host strain TG1Tr
- Optimised antibody expression strain HB2151
- Controls: anti-beta-galactosidase & anti-bovine ubiquitin
For further information and troubleshooting tips
please see the
THIS LIBRARY IS PROVIDED AS
TOOL AND IS NOT INTENDED TO BE USED
IN DRUG DISCOVERY AS THE BASIS FOR NOVEL THERAPEUTIC AGENTS.
THE MTA UNDER WHICH THIS PRODUCT IS RELEASED SETS OUT THE RIGHTS
THAT THE ORIGINATING ORGANISATION (MEDICAL RESEARCH COUNCIL) IS
ABLE TO GRANT. SHOULD YOU WISH TO COMMERCIALISE AN ANTIBODY
DEVELOPED FROM THIS LIBRARY, IT IS LIKELY THAT YOU WILL REQUIRE A
LICENSE FROM SEVERAL COMPANIES, AT LEAST ONE OF WHICH IS ONLY
AVAILABLE TO COMMERCIAL ENTITIES, NOT ACADEMIC ORGANISATIONS.
Please order using our Quick Buy tool.